Gnant M, Filipits M et al. on behalf of Austrian Breast and Colorectal Cancer Study Group. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol. 2014 Feb;25(2):339-45.
See articleMartin M, Gonzalez-Rivera M, Morales S, Haba-Rodriguez J, Gonzalez-Cortijo L, Manso L et al. Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor-positive, HER2-negative, node-negative early-stage breast cancer. Curr Med Res Opin. 2015:1-28.”
See article
Prat A, Galvan P, Jimenez B, Buckingham W, Jeiranian HA, Schaper C et al. Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay. Clin Cancer Res. 2015.Harbeck et al.”
See articleGnant M, Sestak I, Filipits M, Dowsett M, Balic M, Lopez-Knowles E et al. Identifying Clinically Relevant Prognostic Subgroups of Postmenopausal Women with Node-positive Hormone Receptor Positive Early Stage Breast Cancer Treated with Endocrine Therapy: A combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and Intrinsic Subtype. 2015 Aug;26(8):1685-91.”
See articleWallden et al. Development and Verification of the PAM50-based Prosigna Breast Cancer Gene Signature Assay. BMC Med Genomics. 2015;8:54.”
See articleLigibel JA, Cirrincione CT et al. Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). J Natl Cancer Inst. 2015 Jun 25;107(9).
See articleLiu S, Chapman JA et al. Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial. Breast Cancer Res Treat. 2015 Jan;149(2):439-48.
See articleSestak I, Cuzick J et al. Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score. J Clin Oncol. 2015 Mar 10;33(8):916-22.).
See articleDowsett M, Sestak I, Lopez-Knowles E, et al. Comparison of PAM50 risk of recurrence score with Oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol. 2013;31(22):2783-2790.
See articleGnant M, Filipits M, Mlineritsch B, et al; Austrian Breast and Colorectal Cancer Study Group. Clinical validation of the PAM50 risk of recurrence (ROR) score for predicting residual risk of distant-recurrence (DR) after endocrine therapy in postmenopausal women with HR+ early breast cancer (EBC): an ABCSG study. Presented at: San Antonio Breast Cancer Symposium; December 4-8, 2012; San Antonio, TX. Abstract P2-10-02.
See articleGnant M, Filipits M, Dubsky P, et al. Predicting risk for late metastasis: the PAM50 risk of recurrence (ROR) score after 5 years of endocrine therapy in postmenopausal women with HR+ early breast cancer: a study on 1,478 patients from the ABCSG-8 trial. Presented at: European Society for Medical Oncology IMPAKT 2013 Breast Cancer Conference; May 2-4, 2013; Brussels, Belgium. Abstract 53O_PR.
See articleSestak I, Dowsett M, Sgroi D, et al. Comparison of five different scores for the prediction of late recurrence for oestrogen receptor-positive breast cancer. Presented at: European Society for Medical Oncology IMPAKT 2013 Breast Cancer Conference; May 2-4, 2013; Brussels, Belgium. Abstract 540_PR.
See articleSestak I, Dowsett M, Zabaglo L, et al. Factors predicting late recurrence for estrogen receptor–positive breast cancer. J Natl Cancer Inst. 2013;105(19):1504-1511.
See articleNielsen T, Wallden B, Schaper C, et al. Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens [published online ahead of print March 13, 2014]. BMC Cancer. doi:10.1186/1471-2407-14-177.
See article
Gnant M, Dowsett M, Filipits M, et al. Identifying clinically relevant prognostic subgroups in node-positive postmenopausal HR+ early breast cancer patients treated with endocrine therapy: a combined analysis of 2,485 patients from ABCSG-8 and ATAC using the PAM50 risk of recurrence (ROR) score and intrinsic subtype. Presented at: 2013 American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2013; Chicago, IL. Abstract 506.
See articleGnant M, Filipits M, Greil R, et al; Austrian Breast and Colorectal Cancer Study Group. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol. 2014;25(2):339-345.
See articleFilipits M, Nielsen TO, Rudas M, et al; Austrian Breast and Colorectal Cancer Study Group. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer [published online ahead of print February 11, 2014]. Clin Cancer Res. 2014;20(5):1298-1305. doi:10.1158/1078-0432.CCR-13-1845.
See articleSestak I, Cuzick J, Dowsett M, et al; Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score. J Clin Oncol. 2014 Oct 20. pii: JCO.2014.55.6894.
See article
